ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older¹:

• Cryopyrin-associated periodic syndromes (CAPS), including:
  • Muckle-Wells syndrome (MWS)
  • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
  • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
• Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS).
• Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).
• Familial Mediterranean fever (FMF). ILARIS should be given in combination with colchicine, if appropriate.

ILARIS is the first and only selective IL-1β inhibitor for the treatment of FMF, HIDS/MKD, TRAPS and CAPS in adults, adolescents and children aged ≥2 years¹

ILARIS is a fully human monoclonal antibody that neutralises IL-1β to reduce inflammation.¹

IL-1β is a proinflammatory cytokine that plays a key role in autoinflammatory diseases.^1,2

Image created using information from references 1–3.

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; IL, interleukin; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

References     

1. ILARIS^® (canakinumab) Summary of Product Characteristics.     
2. Lachmann HJ et al. Arthritis Rheum 2011;63(2):314–324.     
3. Lin YT et al. Autoimmun Rev 2011;10(8):482–489.